242 filings
Page 4 of 13
8-K
3gfy pd6m5uc5n
13 Aug 21
Diffusion Pharmaceuticals Reports Q2 Financial Results
4:30pm
8-K
yw66c0 3uw4cnc
30 Jun 21
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
4:33pm
8-K
05wc 9gvcb1iyw9
29 Jun 21
Submission of Matters to a Vote of Security Holders
9:05am
8-K
i5lxobt3 8e
12 May 21
Diffusion Pharmaceuticals Reports First Quarter Financial Results
7:30am
8-K
49hu apfuns0yy1c
7 May 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:07pm
8-K
slhduh 5i99
25 Mar 21
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
5:20pm
8-K
ytev9lsefu9e6 s1zbe5
18 Mar 21
Regulation FD Disclosure
4:14pm
8-K
2zm2tl4hc
17 Mar 21
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
4:36pm
8-K
ai8eel6
8 Mar 21
Regulation FD Disclosure
4:10pm
8-K
37e8fb8w
18 Feb 21
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
4:52pm
8-K
r7uochp cxasci5fdz
16 Feb 21
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
8:10am
8-K
j7uagh0
12 Feb 21
Note Regarding Forward-looking Statements
8:19am
8-K
lyo bne7t8nxxrnni14a
26 Jan 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:50pm
8-K
7w3 v3ct5
8 Jan 21
Regulation FD Disclosure
4:07pm
8-K
ir5takbw
14 Dec 20
Regulation FD Disclosure
11:32am
8-K
1izt9oo2pbj8nz
12 Nov 20
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
4:57pm
8-K
8ntlqqjaco33 4u
20 Oct 20
Diffusion Pharmaceuticals Appoints Dr. Chris Galloway as Chief Medical Officer
5:30pm
8-K
4elo9jwvllpwgevi9wm
9 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
kd2p x6oqj75
25 Sep 20
Diffusion Pharmaceuticals Strengthens Management Team with Appointmentof William Elder as General Counsel and Corporate Secretary
4:57pm
8-K
z4wsikf
15 Sep 20
Regulation FD Disclosure
2:50pm